{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:30:55Z","timestamp":1792229455487,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0096-2014"],"award-info":[{"award-number":["PI-0096-2014"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0135-2010"],"award-info":[{"award-number":["PI-0135-2010"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0306-2012"],"award-info":[{"award-number":["PI-0306-2012"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/01262"],"award-info":[{"award-number":["PI15\/01262"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI12\/01104"],"award-info":[{"award-number":["PI12\/01104"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI12\/00137"],"award-info":[{"award-number":["FIS PI12\/00137"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RTICC RD12\/0036\/0028"],"award-info":[{"award-number":["RTICC RD12\/0036\/0028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00045"],"award-info":[{"award-number":["PI15\/00045"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012093","name":"Fundaci\u00f3 Institut de Recerca Hospital Universitari Vall d\u2019Hebron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003330","name":"Secretar\u00eda de Estado de Investigacion, Desarrollo e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ctrv.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T06:42:33Z","timestamp":1468132953000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"special_numbering":"C","title":["The cancer stem-cell signaling network and resistance to therapy"],"prefix":"10.1016","volume":"49","author":[{"given":"A.","family":"Carnero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Garcia-Mayea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.T.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"LLeonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.07.001_b0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature11344","article-title":"Defining the mode of tumour growth by clonal analysis","volume":"488","author":"Driessens","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2016.07.001_b0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM198809013190901","article-title":"Genetic alterations during colorectal-tumor development","volume":"319","author":"Vogelstein","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.07.001_b0015","article-title":"Hypoxic microenvironment as determinant of Cancer stem cells evolution","volume":"1","author":"Carnero","year":"2015","journal-title":"Inside Cell"},{"key":"10.1016\/j.ctrv.2016.07.001_b0020","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrc2499","article-title":"Cancer stem cells in solid tumours: accumulating evidence and unresolved questions","volume":"8","author":"Visvader","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2016.07.001_b0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2016.07.001_b0030","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/hep.25776","article-title":"Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells","volume":"56","author":"Chow","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2016.07.001_b0035","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2016.07.001_b0040","doi-asserted-by":"crossref","first-page":"42019","DOI":"10.18632\/oncotarget.5714","article-title":"CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis","volume":"6","author":"Yiming","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.07.001_b0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1471-2407-11-418","article-title":"CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers","volume":"11","author":"Olsson","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2016.07.001_b0050","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1158\/1078-0432.CCR-12-1379","article-title":"Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF-03084014 in breast cancer models","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0055","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1038\/onc.2008.149","article-title":"ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor","volume":"27","author":"Osipo","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2016.07.001_b0060","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.07.001_b0065","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","article-title":"Identification of cells initiating human melanomas","volume":"451","author":"Schatton","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2016.07.001_b0070","doi-asserted-by":"crossref","first-page":"e76550","DOI":"10.1371\/journal.pone.0076550","article-title":"The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis","volume":"8","author":"Wouters","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2016.07.001_b0075","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1158\/0008-5472.CAN-04-3327","article-title":"ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma","volume":"65","author":"Frank","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0080","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-14-0011","article-title":"CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance","volume":"20","author":"Yoon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clim.2013.07.006","article-title":"Cytokine-induced killer (CIK) cells bound with anti-CD3\/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo","volume":"149","author":"Huang","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.neo.2015.06.002","article-title":"Human renal normal, tumoral, and cancer stem cells express membrane-bound interleukin-15 isoforms displaying different functions","volume":"17","author":"Azzi","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2016.07.001_b0095","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2016.07.001_b0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ccr.2012.07.016","article-title":"Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells","volume":"22","author":"Domingo-Domenech","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2016.07.001_b0105","doi-asserted-by":"crossref","first-page":"11717","DOI":"10.1073\/pnas.1120068109","article-title":"Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors","volume":"109","author":"Gurney","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2016.07.001_b0110","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1073\/pnas.1424171112","article-title":"Suppression of cancer relapse and metastasis by inhibiting cancer stemness","volume":"112","author":"Li","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2016.07.001_b0115","article-title":"A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma (laBCC): the Vismodegib Neoadjuvant (VISMONEO) study","volume":"32","author":"L.M.","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0120","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/jco.2014.32.15_suppl.2527","article-title":"A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors","volume":"32","author":"Scott","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0125","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/jco.2015.33.15_suppl.3615","article-title":"Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer","volume":"33","author":"Derek","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0130","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","article-title":"Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors","volume":"30","author":"Tolcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","article-title":"A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014","author":"Messersmith","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0140","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1158\/1078-0432.CCR-12-2119","article-title":"Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade","volume":"19","author":"Chu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","article-title":"Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis","volume":"9","author":"Shibuya","year":"2006","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ctrv.2016.07.001_b0150","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/bjc.2013.380","article-title":"A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004\/NCI 8503)","volume":"109","author":"Sahebjam","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2016.07.001_b0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2016.07.001_b0160","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1038\/cddis.2015.171","article-title":"Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition","volume":"6","author":"Lee","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2016.07.001_b0165","doi-asserted-by":"crossref","first-page":"651","DOI":"10.18632\/oncotarget.2892","article-title":"Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells","volume":"6","author":"Shibuya","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.07.001_b0170","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1038\/onc.2014.320","article-title":"How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?","volume":"34","author":"Lincet","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2016.07.001_b0175","doi-asserted-by":"crossref","first-page":"896","DOI":"10.18632\/oncotarget.387","article-title":"Metformin: multi-faceted protection against cancer","volume":"2","author":"Del Barco","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.07.001_b0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1158\/0008-5472.177.65.1","article-title":"Glycolytic enzymes can modulate cellular life span","volume":"65","author":"Kondoh","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0185","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/ars.2006.1467","article-title":"A high glycolytic flux supports the proliferative potential of murine embryonic stem cells","volume":"9","author":"Kondoh","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.ctrv.2016.07.001_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/nature15726","article-title":"Oxidative stress inhibits distant metastasis by human melanoma cells","author":"Piskounova","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2016.07.001_b0195","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/carcin\/bgm124","article-title":"MAP17 enhances the malignant behavior of tumor cells through ROS increase","volume":"28","author":"Guijarro","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctrv.2016.07.001_b0200","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-14-1053","article-title":"MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFkappaB activation in breast cancer","volume":"14","author":"Munoz-Galvan","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2016.07.001_b0205","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1080\/15548627.2015.1063764","article-title":"Disruption of the ribosomal P complex leads to stress-induced autophagy","volume":"11","author":"Artero-Castro","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.ctrv.2016.07.001_b0210","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1158\/0008-5472.CAN-05-1162","article-title":"Resistance to paclitaxel is proportional to cellular total antioxidant capacity","volume":"65","author":"Ramanathan","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0215","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"issue":"Suppl 3","key":"10.1016\/j.ctrv.2016.07.001_b0220","doi-asserted-by":"crossref","first-page":"S539","DOI":"10.1245\/s10434-011-2040-5","article-title":"Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon","volume":"19","author":"Kim","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0225","doi-asserted-by":"crossref","first-page":"8742","DOI":"10.1073\/pnas.90.18.8742","article-title":"Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes","volume":"90","author":"Uchida","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2016.07.001_b0230","first-page":"5373","article-title":"Cyclophosphamide resistance in medulloblastoma","volume":"52","author":"Friedman","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0235","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1101\/gad.2051011","article-title":"Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis","volume":"25","author":"Wei","year":"2011","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2016.07.001_b0240","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/stem.1746","article-title":"Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1","volume":"32","author":"Choi","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.ctrv.2016.07.001_b0245","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc2950","article-title":"What is the malignant nature of human ductal carcinoma in situ?","volume":"11","author":"Espina","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2016.07.001_b0250","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canlet.2015.02.045","article-title":"Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment","volume":"361","author":"Yang","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2016.07.001_b0255","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/emboj.2013.123","article-title":"Autolysosomal beta-catenin degradation regulates Wnt-autophagy-p62 crosstalk","volume":"32","author":"Petherick","year":"2013","journal-title":"EMBO J"},{"key":"10.1016\/j.ctrv.2016.07.001_b0260","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/hep.26394","article-title":"Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells","volume":"58","author":"Wang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2016.07.001_b0265","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/jpi.12170","article-title":"Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells","volume":"57","author":"Martin","year":"2014","journal-title":"J Pineal Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0270","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1158\/0008-5472.CAN-11-3567","article-title":"CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells","volume":"72","author":"Tsuyada","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0275","doi-asserted-by":"crossref","first-page":"e0127517","DOI":"10.1371\/journal.pone.0127517","article-title":"Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties","volume":"10","author":"Bhuvanalakshmi","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2016.07.001_b0280","doi-asserted-by":"crossref","first-page":"38901","DOI":"10.18632\/oncotarget.5644","article-title":"CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer","volume":"6","author":"Ding","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.07.001_b0285","article-title":"Oncogenic roles and drug target of CXCR4\/CXCL12 axis in lung cancer and cancer stem cell","author":"Wang","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0290","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2016.07.001_b0295","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/onc.2015.66","article-title":"The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells","volume":"35","author":"Boyle","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2016.07.001_b0300","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/ijc.29326","article-title":"Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma","volume":"136","author":"Bernard","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2016.07.001_b0305","doi-asserted-by":"crossref","first-page":"908","DOI":"10.18632\/oncotarget.1484","article-title":"A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor","volume":"5","author":"Burke","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.07.001_b0310","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1158\/0008-5472.CAN-04-0289","article-title":"Quantifying transient hypoxia in human tumor xenografts by flow cytometry","volume":"64","author":"Bennewith","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0315","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1073\/pnas.1424795112","article-title":"CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer","volume":"112","author":"Cheah","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2016.07.001_b0320","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4049\/jimmunol.1301342","article-title":"Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4","volume":"192","author":"Volonte","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1172\/JCI39397","article-title":"CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts","volume":"120","author":"Ginestier","year":"2010","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ctrv.2016.07.001_b0330","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/intimm\/dxp047","article-title":"Natural killer cells kill human melanoma cells with characteristics of cancer stem cells","volume":"21","author":"Pietra","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0335","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cyto.2004.06.010","article-title":"Overview of interleukin-2 function, production and clinical applications","volume":"28","author":"Gaffen","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.ctrv.2016.07.001_b0340","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/CJI.0b013e31827806e6","article-title":"Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?","volume":"35","author":"Klebanoff","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2016.07.001_b0345","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.ctrv.2016.07.001_b0350","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","article-title":"Therapy-induced tumour secretomes promote resistance and tumour progression","volume":"520","author":"Obenauf","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2016.07.001_b0355","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nbt.1607","article-title":"Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML","volume":"28","author":"Saito","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0360","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jnci\/djn123","article-title":"Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy","volume":"100","author":"Li","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2016.07.001_b0365","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2008.03.022","article-title":"A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes","volume":"129","author":"Liu","year":"2008","journal-title":"J Controlled Release"},{"key":"10.1016\/j.ctrv.2016.07.001_b0370","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2016.07.001_b0375","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0380","doi-asserted-by":"crossref","first-page":"9394","DOI":"10.1158\/0008-5472.CAN-08-2815","article-title":"Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells","volume":"68","author":"Tazzari","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0385","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1186\/bcr2945","article-title":"Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL","volume":"13","author":"Piggott","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0390","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/0008-5472.CAN-13-2309","article-title":"CD44v8-10 is a cancer-specific marker for gastric cancer stem cells","volume":"74","author":"Lau","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0395","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1016\/j.biomaterials.2014.07.033","article-title":"The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells","volume":"35","author":"Yao","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ctrv.2016.07.001_b0400","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.1016\/j.biomaterials.2013.06.004","article-title":"Targeted delivery of miR-200c\/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles","volume":"34","author":"Liu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ctrv.2016.07.001_b0405","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/157340611794859325","article-title":"Interaction of mesalasine (5-ASA) with translational initiation factors eIF4 partially explains 5-ASA anti-inflammatory and anti-neoplastic activities","volume":"7","author":"Lyakhovich","year":"2011","journal-title":"Med Chem"},{"key":"10.1016\/j.ctrv.2016.07.001_b0410","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/labinvest.2014.133","article-title":"Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse\/metastasis","volume":"95","author":"Kantara","year":"2015","journal-title":"Lab Invest"},{"key":"10.1016\/j.ctrv.2016.07.001_b0415","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","article-title":"A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia","volume":"137","author":"Diaz-Padilla","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0420","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/cncr.29055","article-title":"Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933","volume":"121","author":"Lee","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.07.001_b0425","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10637-013-9965-4","article-title":"A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078\/CTEP 8575)","volume":"32","author":"Richter","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2016.07.001_b0430","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1038\/bcj.2015.80","article-title":"A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"5","author":"Papayannidis","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2016.07.001_b0435","doi-asserted-by":"crossref","first-page":"a000539","DOI":"10.1101\/mcs.a000539","article-title":"Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the gamma-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case","volume":"1","author":"Knoechel","year":"2015","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.ctrv.2016.07.001_b0440","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acsmedchemlett.5b00001","article-title":"Discovery of clinical candidate BMS-906024: a potent pan-notch inhibitor for the treatment of leukemia and solid tumors","volume":"6","author":"Gavai","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ctrv.2016.07.001_b0445","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","article-title":"Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0450","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.08.005","article-title":"Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28","volume":"146","author":"Le","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2016.07.001_b0460","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1158\/1078-0432.CCR-11-1111","article-title":"Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8(+) T cells","volume":"17","author":"Visus","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0465","doi-asserted-by":"crossref","first-page":"16476","DOI":"10.1074\/jbc.M112.448142","article-title":"Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem\/progenitor cells to battle prostate cancer","volume":"288","author":"Yang","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2016.07.001_b0470","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.4049\/jimmunol.0802845","article-title":"NK cells recognize and kill human glioblastoma cells with stem cell-like properties","volume":"182","author":"Castriconi","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2016.07.001_b0475","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cellsig.2013.01.007","article-title":"Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells","volume":"25","author":"Kim","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.ctrv.2016.07.001_b0480","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.07.001_b0485","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2016.07.001_b0490","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-12-3349","article-title":"HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab","volume":"73","author":"Ithimakin","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.07.001_b0495","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/bjc.2011.293","article-title":"Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours","volume":"105","author":"Nicol","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2016.07.001_b0500","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1073\/pnas.96.15.8639","article-title":"CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells","volume":"96","author":"Bonnet","year":"1999","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:21:32Z","timestamp":1777555292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216300573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":100,"alternative-id":["S0305737216300573"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.07.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cancer stem-cell signaling network and resistance to therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}